CA1050887A - Composition containing d- and/or 1-cyanocyproheptadine - Google Patents
Composition containing d- and/or 1-cyanocyproheptadineInfo
- Publication number
- CA1050887A CA1050887A CA231,114A CA231114A CA1050887A CA 1050887 A CA1050887 A CA 1050887A CA 231114 A CA231114 A CA 231114A CA 1050887 A CA1050887 A CA 1050887A
- Authority
- CA
- Canada
- Prior art keywords
- cyano
- ylidene
- dibenzo
- methyl
- piperidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 239000002253 acid Substances 0.000 claims abstract description 10
- 239000002552 dosage form Substances 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- VQMCMVDCTCDPCA-UHFFFAOYSA-N 11-(1-methylpiperidin-4-ylidene)dibenzo[1,3-e:1',2'-f][7]annulene-2-carbonitrile Chemical compound C1CN(C)CCC1=C1C2=CC(C#N)=CC=C2C=CC2=CC=CC=C21 VQMCMVDCTCDPCA-UHFFFAOYSA-N 0.000 claims abstract 6
- 230000000875 corresponding effect Effects 0.000 claims abstract 6
- 231100000252 nontoxic Toxicity 0.000 claims abstract 6
- 230000003000 nontoxic effect Effects 0.000 claims abstract 6
- 239000003937 drug carrier Substances 0.000 claims abstract 5
- 230000001078 anti-cholinergic effect Effects 0.000 abstract description 4
- 230000002093 peripheral effect Effects 0.000 abstract description 4
- 230000002936 tranquilizing effect Effects 0.000 abstract description 4
- 239000000812 cholinergic antagonist Substances 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000003176 neuroleptic agent Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- CMIBUZBMZCBCAT-HZPDHXFCSA-N (2r,3r)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(=O)C1=CC=C(C)C=C1 CMIBUZBMZCBCAT-HZPDHXFCSA-N 0.000 description 1
- CMIBUZBMZCBCAT-HOTGVXAUSA-N (2s,3s)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)O[C@H](C(O)=O)[C@@H](C(O)=O)OC(=O)C1=CC=C(C)C=C1 CMIBUZBMZCBCAT-HOTGVXAUSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OXHNLMTVIGZXSG-UHFFFAOYSA-N 1-Methylpyrrole Chemical compound CN1C=CC=C1 OXHNLMTVIGZXSG-UHFFFAOYSA-N 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000212342 Sium Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002948 appetite stimulant Substances 0.000 description 1
- 229940029995 appetite stimulants Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940116298 l- malic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48697874A | 1974-07-10 | 1974-07-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1050887A true CA1050887A (en) | 1979-03-20 |
Family
ID=23933896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA231,114A Expired CA1050887A (en) | 1974-07-10 | 1975-07-09 | Composition containing d- and/or 1-cyanocyproheptadine |
Country Status (22)
-
1975
- 1975-06-24 SE SE7507241A patent/SE424989B/xx unknown
- 1975-06-24 FI FI751865A patent/FI58914C/fi not_active IP Right Cessation
- 1975-06-25 DK DK288575A patent/DK288575A/da not_active Application Discontinuation
- 1975-06-25 NL NL7507568A patent/NL7507568A/xx not_active Application Discontinuation
- 1975-06-27 NO NO752346A patent/NO752346L/no unknown
- 1975-07-01 IL IL47616A patent/IL47616A/xx unknown
- 1975-07-02 PH PH17341A patent/PH12160A/en unknown
- 1975-07-03 ES ES439125A patent/ES439125A1/es not_active Expired
- 1975-07-03 HU HU75ME00001875A patent/HU171309B/hu unknown
- 1975-07-03 FR FR7520899A patent/FR2277583A1/fr active Granted
- 1975-07-03 GB GB28109/75A patent/GB1479380A/en not_active Expired
- 1975-07-08 PL PL1975181930A patent/PL101286B1/pl unknown
- 1975-07-08 AT AT526075A patent/AT343661B/de not_active IP Right Cessation
- 1975-07-08 LU LU72928A patent/LU72928A1/xx unknown
- 1975-07-08 IE IE1516/75A patent/IE41488B1/en unknown
- 1975-07-09 ZA ZA754405A patent/ZA754405B/xx unknown
- 1975-07-09 CA CA231,114A patent/CA1050887A/en not_active Expired
- 1975-07-09 CH CH896575A patent/CH612182A5/xx not_active IP Right Cessation
- 1975-07-09 DE DE19752530686 patent/DE2530686A1/de active Pending
- 1975-07-09 BE BE158128A patent/BE831170A/xx not_active IP Right Cessation
- 1975-07-10 JP JP50084050A patent/JPS5134166A/ja active Granted
- 1975-07-10 AR AR259505A patent/AR210995A1/es active
Also Published As
| Publication number | Publication date |
|---|---|
| IL47616A (en) | 1978-07-31 |
| BE831170A (fr) | 1976-01-09 |
| ATA526075A (de) | 1977-10-15 |
| FR2277583B1 (enrdf_load_stackoverflow) | 1980-05-16 |
| AU8268575A (en) | 1977-01-06 |
| FI58914B (fi) | 1981-01-30 |
| CH612182A5 (en) | 1979-07-13 |
| NO752346L (enrdf_load_stackoverflow) | 1976-01-13 |
| SE7507241L (sv) | 1976-01-12 |
| SE424989B (sv) | 1982-08-23 |
| DK288575A (da) | 1976-01-11 |
| JPS5134166A (en) | 1976-03-23 |
| IL47616A0 (en) | 1975-10-15 |
| ZA754405B (en) | 1977-02-23 |
| FI751865A7 (enrdf_load_stackoverflow) | 1976-01-11 |
| JPS5622864B2 (enrdf_load_stackoverflow) | 1981-05-27 |
| AT343661B (de) | 1978-06-12 |
| PH12160A (en) | 1978-11-10 |
| ES439125A1 (es) | 1977-06-01 |
| NL7507568A (nl) | 1976-01-13 |
| HU171309B (hu) | 1977-12-28 |
| LU72928A1 (enrdf_load_stackoverflow) | 1976-05-31 |
| PL101286B1 (pl) | 1978-12-30 |
| AR210995A1 (es) | 1977-10-14 |
| IE41488B1 (en) | 1980-01-16 |
| FR2277583A1 (fr) | 1976-02-06 |
| FI58914C (fi) | 1981-05-11 |
| GB1479380A (en) | 1977-07-13 |
| DE2530686A1 (de) | 1976-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6049192B2 (ja) | 新規置換ベンズアミド、その製造方法及びこれを有効成分とする向精神薬 | |
| HK18496A (en) | Novel crystalline 7-(2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid (syn isomer) | |
| US5350582A (en) | Stable formulation of enalapril salt, a process for the preparation thereof and the use thereof | |
| US4147780A (en) | α-Amino-phosphonous acids for inhibiting bacteria and yeast | |
| JPH06508853A (ja) | プレウロムチリン誘導体 | |
| CA1050887A (en) | Composition containing d- and/or 1-cyanocyproheptadine | |
| US4091105A (en) | 2-Imino-3-aminothiazolidines and indoleamine-N-methyltransferase inhibition | |
| US4044130A (en) | Compositions for the control of microorganisms | |
| JPS6117544A (ja) | 新規化合物，その製造方法及び用途 | |
| US4279914A (en) | Thrombocyte aggregation inhibiting composition and methods | |
| US4060622A (en) | (+) AND (-) 1-Methyl-4-(3-cyano-5H-dibenzo(a,d)-cyclohepten-5-ylidene)piperidine containing compositions and methods for using same | |
| CA1055044A (en) | Phenylalkyl esters of amino-acids having antidepressive activity | |
| FR2539990A1 (fr) | Composition pharmaceutique a action psychotrope dopaminergique contenant une 2-piperazinopyrimidine | |
| US4349548A (en) | Octahydrobenzo[6,7]cyclohept[1,2-b]-1,4-oxazines, compositions and use | |
| US4160031A (en) | Antihistaminic and appetite stimulating 10,11-dihydro-3-carboxycyproheptadine | |
| US4822778A (en) | Membrane stabilizing phenoxy-piperidine compounds and pharmaceutical compositions employing such compounds | |
| FR2547821A1 (fr) | Sel de 2-piperazinopyrimidine, procede pour sa preparation et compositions pharmaceutiques en contenant | |
| FR2501682A1 (fr) | Trifluoromethylphenylpyridines a activite anorexigene, un procede de preparation et compositions pharmaceutiques en contenant | |
| CA1041544A (en) | Optically active 2,3-cis-1,2,3,4-tetrahydro-5-(2-hydroxy-3-(tertbutylamino)-propoxy)-2,3-naphthalenediols | |
| US3351530A (en) | Compositions for producing spasmolytic activity comprising 3-tropanyl-2-phenylacrylate compounds | |
| US3676432A (en) | 11,12-DIHYDRODIBENZ{8 b,f{9 AZOCIN-6(5H)-ONES | |
| US4098901A (en) | Trifluoromethyl substituted compounds having antidepressive activity | |
| US3335184A (en) | Ortho-diisopropylaminoethoxybutyrophenone and hydrochloride thereof | |
| US4334071A (en) | 17-Cyclobutylmethyl-3-hydroxy-8β-methyl-6-methylene-morphinane methanesulfonate | |
| US4548947A (en) | 1-(Substituted-aryl)-dihydro-1H-pyrrolizine-3,5-[2H,6H-]diones and use for reversing amnesia |